• Technical Name
  • Development of selective histone deacetylase 6 inhibitor for the treatment of Alzheimer's disease
  • Operator
  • School of Pharmacy, National Taiwan University
  • Booth
  • Online display only
  • Contact
  • 黃芳儀
  • Email
  • d01423203@ntu.edu.tw
Technical Description This technology is exploring a new use for the NTUP413 in Alzheimer's disease, which has been shown to be a potential therapeutic agent for neurodegenerative diseases.
Scientific Breakthrough NTUP413 is a high selective HDAC6 inhibitorwell tolerated without cardiac toxicity. It decreases the levels of phosphor-tau/aggregation of tau,reduces neuronal apoptosis. NTUP413 can ameliorate learningmemory impairment in animal models. Oral administration NTUP413 can cross the blood-brain barrier. It shows that NTUP413 has the potential to develop as an AD therapeutic drug.
Industrial Applicability NTUP413 has potent HDAC6 inhibitory activityhigh selectivity for HDAC6, which can reduce side effects. Oral administration NTUP413 can penetrate blood-brain barrier it can reduce tau phosphorylation/aggregationsignificantly ameliorate learningmemory impairment by in vitroin vivo models. It shows that NTUP413 has the potential to further develop as an AD therapeutic drug.